Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence.
about
Ovarian cancer, the coagulation pathway, and inflammationCan heparins stimulate bone cancer stem cells and interfere with tumorigenesis?Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.From heparins to factor Xa inhibitors and beyond.Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review.Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.Cancer, clots and consensus: new understanding of an old problem.Heparan sulfate-protein binding specificity.In vitro effects of Apixaban on 5 different cancer cell lines.Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma.Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition.Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.Comparative pharmacodynamic assessment of the antiangiogenesis activity of heparin and low-molecular-weight heparin fractions: structure-function relationship.Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation
P2860
Q24816796-7F54AD27-DB57-4C04-901C-296E57B0C23DQ26852760-0DE85252-329C-4187-9B3F-973932F6D123Q35174604-2AE9A5EB-826D-4E71-BDD5-866884CD28FDQ36034728-693C798F-FE24-4616-8884-705356843962Q36734996-B92A3D61-07C0-4E34-A632-03811BB4A49BQ37023306-4D786368-C4DE-4B59-AA63-E76B8260707AQ37393386-AEA13960-5D4E-43AB-8D12-354B740D36E4Q38134808-F87ED49C-9A75-4221-8382-4A2C0F50A62AQ42375694-812B829A-1169-40D3-9880-CC709A790A4BQ44521532-26B2BE85-4FDC-41D7-B149-5CAFFC48FF52Q47117429-7F69B31A-D0FC-474C-8779-1510864ADD61Q47175930-83C5DD90-D640-4EE3-B44C-3C5947931952Q47326919-9DD1660A-C1DB-4BE3-B638-D3B2864BF9FFQ47448168-874C2445-B8B1-4C58-8B3B-2A127978C3E0Q57794120-B8E56E24-08F2-477E-9B5A-0C4C6561C3A9
P2860
Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Improved cancer mortality with ...... ent: a review of the evidence.
@ast
Improved cancer mortality with ...... ent: a review of the evidence.
@en
Improved cancer mortality with ...... ent: a review of the evidence.
@nl
type
label
Improved cancer mortality with ...... ent: a review of the evidence.
@ast
Improved cancer mortality with ...... ent: a review of the evidence.
@en
Improved cancer mortality with ...... ent: a review of the evidence.
@nl
prefLabel
Improved cancer mortality with ...... ent: a review of the evidence.
@ast
Improved cancer mortality with ...... ent: a review of the evidence.
@en
Improved cancer mortality with ...... ent: a review of the evidence.
@nl
P2093
P356
P1476
Improved cancer mortality with ...... ent: a review of the evidence.
@en
P2093
Eric Racine
Judith C Andersen
Leo R Zacharski
Richard H Cosgrove
P356
10.1055/S-2002-20566
P577
2002-02-01T00:00:00Z